A severe case of psoriasis treated with brodalumab after failure of previous biologic therapy - case report
2022
Abstract
Psoriasis vulgaris is a chronic inflammatory disease affecting 2-4% of central European population. In the last years there has been a big progress in understanding the pathophysiology mechanisms of psoriasis which had as a result the discovery of biologic therapy.
Currently we have available several biologic drugs which are blocking several cytokines like tumor necrosis factor α (TNF-α) or interleukin (IL) 17 and 23. This means, that we can be able to offer effective therapy even in the most severe cases.
In this case report we describe the case of a 32year old female patient with severe type of psoriasis responding always temporally to biologic therapy, which is currently treated with brodalumab with very good effect.